Personalized Treatment Strategies
in the Management of Psoriasis
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 10, 2018 to January 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Lilly USA LLC and Novartis Pharmaceuticals
Psoriasis is a complex, chronic, immune-mediated inflammatory
disease that affects approximately 7 million, or just over 2%, of
the population in the United States. The main disease activity
leading to psoriasis occurs within the top 5 layers of the epidermis
and most commonly appears on the skin of the scalp, elbow, knees,
and lumbosacral areas of the body. Psoriasis is a periodic flare-up
of itchy, sharply defined red patches covered by a silvery, flaky
surface. The disease is complex to manage and a patient-centered
treatment approach is encouraged as the goal is to reduce disease
burden, improves quality-of-life, and addresses the risks of
systemic complications and comorbidities. Unfortunately, the disease
is under diagnosed and expensive to treat thus early diagnosis and
treatment are likely to reduce the economic burden. Choosing the
most effective therapy depends on factors such as the location,
severity and type of psoriasis. Topical agents remain the standard
treatment in the first line setting, however patient adherence is
quite poor. Systemic medication is prescribed orally or by injection
while photo or laser therapy are also effective yet expensive and
require frequent doctor visits; adding to the disease burden.
Fortunately, novel oral medications which target small molecules and
biologics have shown efficacy in clinical trials. Recent research
indicates that both IL-23 and IL-17 pathways play important, and
perhaps integral roles in the development of psoriatic plaques.
Upon Completion of this
activity, participants will be able to:
Analyze individualized treatment
plans for patients with psoriasis using clinical safety and
Examine the most up-to-date
diagnostic criteria and standard treatment options for early and
moderate to severe patients with psoriasis
Evaluate practical treatment
considerations for patients with psoriasis who have challenging
Identify recent biological therapies
with interleukin-17 (IL-17) and IL-23 pathway inhibitors in
patients with moderate to severe psoriasis
Assess the improved psoriasis
pathogenesis and how recent developments help increase effective
systemic agents to treat patients
||Junko Takeshita, MD,
Assistant Professor of Dermatology
Assistant Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
Lilly USA LLC and Novartis Pharmaceuticals
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue